De­cen­tral­ized tri­als com­pa­ny Sci­ence 37 to go pri­vate in deal with di­ag­nos­tics start­up eMed

Last year
Startups
Deals

Sanofi part­ners with Syn­thekine in im­munol­o­gy race

Last year
Deals

Bris­tol My­er­s' Op­di­vo fails part two of post-kid­ney can­cer surgery test as com­peti­tor Mer­ck touts new sur­vival da­ta

Last year
R&D
Pharma

Fractyl has the GUTS: Obe­si­ty and di­a­betes biotech charts $99M IPO

Last year
Financing
Cell/Gene Tx

First-ever RNA edit­ing tri­al in US gets clear­ance, pit­ting ‘ex­on edit­ing’ tech­nol­o­gy against vi­sion loss

Last year
R&D

Ex­clu­sive: UK biotech rais­es $33.1M to test CF drug that could work on top of stan­dard of care

Last year
Financing

Sanofi's $1.7B rare dis­ease gam­bit; CAR-T boxed warn­ing saga; New biotechs on Nas­daq; A sell­er's mar­ket for M&A?; and ...

Last year
Weekly

Bio­phar­ma in­dus­try's vac­cine pipeline lacks ‘depth,' with an overem­pha­sis on Covid — re­port

Last year
R&D
Coronavirus

Two new drugs get pos­i­tive rec­om­men­da­tions from EMA com­mit­tee, while two oth­ers get thumbs-down

Last year
Pharma
FDA+

Com­pe­ti­tion en­force­ment led to fair­er prices, in­no­v­a­tive prod­ucts — EC re­port

Last year
Pharma
FDA+

Check your dad jeans — and genes — in J&J's new BR­CA-fo­cused cam­paign

Last year
Pharma
Marketing

Re­mote man­u­fac­tur­ing as­sess­ments: FDA re­vis­es draft guid­ance to in­clude new­ly ex­pand­ed pow­ers

Last year
FDA+
Manufacturing

For biotechs in the in­dus­try’s hand­ful of hot ar­eas, it’s a sell­er’s mar­ket

Last year
Deals

Ab­b­Vie pours $223M in­to build­ing out its bi­o­log­ics ca­pac­i­ty in Sin­ga­pore

Last year
Manufacturing

Mer­ck de­tails win for Keytru­da in blad­der can­cer af­ter surgery

Last year
R&D

Deer­field gives up rights to Windtree ther­a­py; Tra­vere inks deal with Re­nalys in Asia; Celu­lar­i­ty rais­es $21M

Last year
News Briefing

In­no­va­tion En­deav­ors’ Joel Dud­ley on grow­ing in­ter­est in life sci­ences with new fund — and why he hates ...

Last year
People
Financing

UK's 're­silien­t' life sci­ences sec­tor hopes for up­turn af­ter de­creas­es in fi­nanc­ing, ven­ture cap­i­tal in 2023 — ...

Last year
Financing

Lon­za eyes rev­enue growth this year af­ter 2023 chal­lenges, plans to close sec­ond bi­o­log­ics site in a month

Last year
Manufacturing

Bay­er’s ra­di­ol­o­gy head plans re­tire­ment; Ex-Sanofi chief Olivi­er Brandi­court joins BeiGene’s board

Last year
People
Peer Review

Ex­clu­sive: Strand lays off 18% of staff as its first mR­NA ther­a­pies head in­to the clin­ic

Last year
People
R&D

Ar­riVent prices $175M IPO in back-to-back on­col­o­gy biotech list­ings

Last year
Financing

Sen­ate Fi­nance Com­mit­tee plots ways to tweak Medicare to re­duce ster­ile in­jectable short­ages

Last year
Pharma

As PBMs face threats in Wash­ing­ton, in­dus­try trade group poured mil­lions more in­to lob­by­ing

Last year
Pharma
FDA+
First page Previous page 211212213214215216217 Next page Last page
A service from the Financial Times